Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Up to now, to our knowledge, there is few randomized, large scale study prospectively and simultaneously comparing the efficacy, adverse effects and patient adherence of these current recommended 1st-line or 2nd-line regimens for H. pylori eradication in and out of our country.

The aims of this study are:

1. to compare the efficacy of high dose dual therapy, sequential therapy and clarithromycin-based triple therapy as 1st-line regimen in H. pylori eradication;

2. to compare the efficacy of high dose dual therapy, sequential therapy and levofloxacin-based triple therapy as rescue regimen in H. pylori eradication;

3. to compare the patient adherence and adverse effects of these treatment regimens;

4. to investigate factors that may influence H. pylori eradication by these treatment regimens;

5. to investigate and analyze the prevalence and trend of antibiotic resistance.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Collaborator: National Science Council, Taiwan
• Treatments: Amoxicillin; Clarithromycin; Levofloxacin; Ofloxacin; Rabeprazole

Criteria

Inclusion Criteria:

• patients having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 18 years and are willing to received eradication therapy.

Exclusion Criteria:

• pregnant or nursing woman

• serious concomitant illness and malignant tumor of any kind

• history of hypersensitivity to test drugs

• serious bleeding during the course of this ulcer

• previous gastric surgery

• receiving bismuth salts, proton pump inhibitors, or antibiotics in the previous month.